[HTML][HTML] Drug and gene delivery to the back of the eye: from bench to bedside

CL Rowe-Rendleman, SA Durazo… - … & visual science, 2014 - iovs.arvojournals.org
CL Rowe-Rendleman, SA Durazo, UB Kompella, KD Rittenhouse, A Di Polo, AL Weiner…
Investigative ophthalmology & visual science, 2014iovs.arvojournals.org
From Bench to Bedside''was held June 15 and 16, 2012, at the University of Colorado
Anschutz Medical Campus in Aurora, Colorado. The SERC provided a diverse group of
approximately 150 scientists and physicians representing industry and academia from 14
countries with a unique opportunity to explore the latest approaches to drug and gene
delivery to the posterior segment of the eye. Unlike the 2009 SERC meeting, which focused
on novel drug delivery platforms while elucidating the anatomic barriers to reach the …
From Bench to Bedside’’was held June 15 and 16, 2012, at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. The SERC provided a diverse group of approximately 150 scientists and physicians representing industry and academia from 14 countries with a unique opportunity to explore the latest approaches to drug and gene delivery to the posterior segment of the eye. Unlike the 2009 SERC meeting, which focused on novel drug delivery platforms while elucidating the anatomic barriers to reach the posterior segment, 1 the most recent meeting explored strategies for bypassing ocular barriers using novel materials, nanoparticulate delivery systems, and gene therapy. It brought together experts in both ophthalmology and tangentially related areas to discuss the application and inherent technical challenges for translating experimental results from the laboratory bench to dependable medical therapies at the bedside and, where possible, it exemplified findings in ocular models with methods and results gleaned from disciplines outside of ophthalmology. The present review of the SERC provides investigators with tools to navigate these nascent approaches by exploring strategies from key laboratory investigations, drug development specialists, and clinical trials. The 2-day conference comprised the following six sessions:(1) barriers to drug delivery and transporter-guided drug design;(2) drug/gene delivery systems and cell therapies for the eye;(3) pharmacokinetics (PK), pharmacodynamics, and alternative routes of drug delivery;(4) nanotechnology for diagnosis and treatment of posterior eye disease;(5) translation of gene delivery for posterior eye disease; and (6) clinical trials.
ARVO Journals